Showing results (61-70 of 135) with videos related to

Sort By:
Pageof 14
Cancer Chemotherapy and Pharmacology|July 21, 2016
A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumabNaoki Takahashi, Satoru Iwasa, Masaru Fukahori, et al.
BMC Cancer|April 15, 2022
Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective studyShigemasa Takamizawa, Tatsunori Shimoi, Masayuki Yoshida, et al.
Breast Cancer (Tokyo, Japan)|August 14, 2024
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabineRui Kitadai, Tatsunori Shimoi, Shu Yazaki, et al.
Critical Care (London, England)|April 23, 2024
Case study observational research: inflammatory cytokines in the bronchial epithelial lining fluid of COVID-19 patients with acute hypoxemic respiratory failureKazuki Sudo, Mao Kinoshita, Ken Kawaguchi, et al.
Frontiers in Medicine|March 13, 2024
Potential marker subset of blood-circulating cytokines on hematopoietic progenitor-to-Th1 pathway in COVID-19Yasuo Takashima, Tohru Inaba, Tasuku Matsuyama, et al.
Anticancer Research|July 3, 2017
Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative IntentYoshitaka Honma, Nobukazu Hokamura, Kengo Nagashima, et al.
Cancer Science|June 16, 2018
PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection systemTatsunori Shimoi, Akinobu Hamada, Marifu Yamagishi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 22, 2019
[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma]Yohei Ohtake, Kazuki Sudo, Yuki Kojima, et al.
British Journal of Cancer|December 15, 2022
Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancerShu Yazaki, Roberto Salgado, Tatsunori Shimoi, et al.
Breast Cancer (Tokyo, Japan)|July 28, 2025
Baseline risk variability by eligibility criteria in Cohort 1 of the monarchE trial for high-risk HR-positive, HER2-negative breast cancerMai Hoshino, Tatsunori Shimoi, Taro Yamanaka, et al.
Pageof 14